The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jul. 22, 2025

Filed:

Feb. 23, 2018
Applicant:

Seoul National University R&db Foundation, Seoul, KR;

Inventors:

Yoon-Keun Kim, Gyeonggi-do, KR;

Taesung Park, Seoul, KR;

Yong Sang Song, Seoul, KR;

Se Ik Kim, Seoul, KR;

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C12Q 1/68 (2018.01); C12Q 1/686 (2018.01); C12Q 1/6886 (2018.01); C12Q 1/689 (2018.01);
U.S. Cl.
CPC ...
C12Q 1/689 (2013.01); C12Q 1/686 (2013.01); C12Q 1/6886 (2013.01); C12Q 2531/113 (2013.01);
Abstract

The present invention relates to a method of diagnosing ovarian cancer through microbial metagenomic analysis, and more particularly to a method of diagnosing ovarian cancer by analyzing an increase or decrease in content of specific bacteria or archaea-derived extracellular vesicles through metagenomic analysis using a subject-derived sample. Extracellular vesicles secreted from microorganisms existing in the environment are absorbed into the human body, and thus may directly affect the occurrence of cancer, and it is difficult to diagnose ovarian cancer early before symptoms thereof so that efficient treatment thereof is difficult. Thus, according to the present invention, a risk for ovarian cancer can be predicted through metagenomic analysis of bacteria-derived extracellular vesicles using a human body-derived sample, and thus the onset of ovarian cancer can be delayed or ovarian cancer can be predicted through appropriate management by early diagnosis and prediction of a risk group for ovarian cancer, and even after ovarian cancer occurs, early diagnosis for ovarian cancer can be implemented, thereby lowering the incidence of ovarian cancer and increasing therapeutic effects.


Find Patent Forward Citations

Loading…